14-day Premium Trial Subscription Sign Up For FreeGet Free

DexCom Stock Forecast NASDAQ:DXCM

Price Target and Analyst Ratings

Most Recent Rating

On September 16, 2021 "Piper Sandler" gave "$550.00 - $650.00" rating for DXCM. The price target was set to $551.67+1.7%.

Last 30 Days

Historical Ratings

Date Rating Action Authority Current Price Target Price
2021-09-16 $550.00 - $650.00 Target Raised by Piper Sandler $565.13 $551.67+1.7%
2021-08-02 $410.00 - $510.00 Target Raised by Morgan Stanley $511.35 $514.41→0.2%
2021-07-30 $468.00 - $546.00 Target Raised by Stephens $515.51 $507.68+11.3%
2021-07-30 $380.00 - $475.00 Target Raised by Wells Fargo & Company $515.51 $456.05→0.8%
2021-07-30 $485.00 - $500.00 Target Raised by SVB Leerink $515.51 $456.05→0.8%
2021-07-30 $500.00 - $525.00 Target Raised by Oppenheimer $515.51 $456.05→0.8%
2021-07-30 $455.00 - $500.00 Target Raised by Canaccord Genuity $515.51 $456.05→0.8%
2021-07-30 $466.00 - $515.00 Target Raised by Raymond James $515.51 $456.05→0.8%
2021-07-30 $460.00 - $520.00 Target Raised by Robert W. Baird $515.51 $456.05→0.8%
2021-07-30 $500.00 - $550.00 Target Raised by Piper Sandler $515.51 $456.05→0.8%
2021-07-21 $540.00 - $525.00 Target Lowered by Cowen $446.98 $447.70+2.9%
2021-07-01 Buy Reiterated by Stephens $426.84 $468.00
2021-05-28 Underweight - Equal Weight Upgraded by Wells Fargo & Company $369.39 $380.00
2021-05-24 Overweight Initiated by Barclays $355.39
2021-05-06 Buy Target Raised by Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell $357.34 $480.00 → $488.00
2021-05-06 Outperform Target Raised by Raymond James $357.34 $449.00 → $466.00
2021-05-06 Buy Target Raised by Canaccord Genuity $357.34 $445.00 → $455.00
2021-04-30 Outperform Target Raised by Raymond James $386.10 $449.00 → $466.00
2021-04-30 Target Raised by Citigroup $386.10 $480.00 → $488.00
2021-04-30 Buy Target Raised by Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell $386.10 $480.00 → $488.00
2021-04-30 Buy Target Raised by Canaccord Genuity $386.10 $445.00 → $455.00
2021-04-21 Overweight Initiated by Atlantic Securities $401.62 $438.00
2021-04-15 Overweight Initiated by Atlantic Securities $399.49 $438.00
2021-02-12 Target Lowered by Citigroup $412.56 $485.00 → $480.00
2021-02-12 Outperform Target Raised by Raymond James $412.56 $415.00 → $449.00
2021-02-12 Equal Weight Target Raised by Morgan Stanley $412.56 $402.00 → $410.00
2021-02-12 Outperform Target Raised by Oppenheimer $412.56 $415.00 → $449.00
2021-01-29 Overweight Target Raised by Piper Sandler $374.85 $465.00 → $500.00
2021-01-06 Neutral - Buy Upgraded by UBS Group $375.92 $410.00 → $445.00
2020-12-15 Equal Weight Target Raised by Morgan Stanley $354.21 $398.00 → $402.00
2020-12-10 Buy Reiterated by Raymond James $347.19
2020-12-10 Buy Target Lowered by Canaccord Genuity $347.19 $475.00 → $435.00
2020-11-20 Buy Reiterated by Piper Sandler $315.87 $465.00
2020-10-28 Outperform Target Lowered by Raymond James $349.12 $450.00 → $438.00
2020-10-28 Buy Target Lowered by Stifel Nicolaus $349.12 $500.00 → $475.00
2020-10-28 Buy Target Lowered by Canaccord Genuity $349.12 $500.00 → $475.00
2020-10-28 Equal Weight Target Lowered by Morgan Stanley $349.12 $428.00 → $398.00
2020-10-02 Equal Weight - Underweight Downgraded by Wells Fargo & Company $384.52 $420.00 → $350.00
2020-07-29 Neutral Target Raised by UBS Group $427.08 $335.00 → $400.00
2020-07-29 Equal Weight - Outperform Target Raised by SVB Leerink $427.08 $465.00 → $485.00
2020-07-29 Overweight Target Raised by Piper Sandler $427.08 $450.00 → $465.00
2020-07-29 Buy Target Raised by Citigroup $427.08 $440.00 → $485.00
2020-07-29 Equal Weight Target Raised by Morgan Stanley $427.08 $377.00 → $428.00
2020-07-29 Buy Target Raised by Canaccord Genuity $427.08 $435.00 → $500.00
2020-07-29 Outperform Target Raised by Raymond James $427.08 $395.00 → $450.00
2020-07-29 Buy Target Raised by Stifel Nicolaus $427.08 $385.00 → $500.00
2020-07-28 Buy Reiterated by Bank of America $417.79 $500.00
2020-07-28 Buy Initiated by Oppenheimer $417.79 $360.00 → $445.00
2020-07-27 Overweight Target Raised by JPMorgan Chase & Co. $423.43 $360.00 → $450.00
2020-07-27 Overweight Target Raised by JPMorgan Chase & Co. $423.43 $360.00 → $450.00
2020-07-07 Positive - Outperform Target Raised by Cowen $425.86 $430.00 → $450.00
2020-06-17 Buy Target Raised by Bank of America $403.18 $375.00 → $500.00
2020-06-09 Outperform Target Raised by Raymond James $380.50 $360.00 → $395.00
2020-06-03 Average - Buy Target Raised by Citigroup $365.86 $361.00 → $440.00
2020-05-27 Overweight Target Raised by Piper Sandler $359.63 $375.00 → $450.00
2020-05-14 Equal Weight Initiated by Wells Fargo & Co $403.05 $420.00
2020-04-30 Neutral Target Raised by UBS Group $335.20 $275.00 → $335.00
2020-04-29 Overweight Target Raised by JPMorgan Chase & Co. $345.47 $300.00 → $360.00
2020-04-29 Buy Target Raised by Stifel Nicolaus $345.47 $270.00 → $385.00
2020-04-29 Equal Weight Target Raised by Morgan Stanley $345.47 $278.00 → $377.00
2020-04-29 Buy Target Raised by Citigroup $345.47 $330.00 → $361.00
2020-04-29 Outperform Target Raised by Robert W. Baird $345.47 $296.00 → $373.00
2020-04-29 Outperform Target Raised by Oppenheimer $345.47 $305.00 → $360.00
2020-04-29 Outperform Target Raised by Cowen $345.47 $300.00 → $360.00
2020-04-29 Overweight Target Raised by Piper Sandler $345.47 $300.00 → $375.00
2020-04-29 Hold Reiterated by BTIG Research $345.47
2020-04-29 Buy Target Raised by Guggenheim $345.47 $385.00 → $395.00
2020-04-27 Outperform Target Raised by Raymond James $335.05 $288.00 → $350.00
2020-04-24 Outperform Target Raised by SVB Leerink $332.44 $316.00 → $385.00

DXCM Stock Trend

The stock lies in the middle of a strong rising trend in the short term and a further rise within the trend is signaled.

Given the current short-term trend, the stock is expected to rise 35.04% during the next 3 months and, with a 90% probability hold a price between $729.89 and $772.70 at the end of this 3-month period.

Data

Date Bottom Mid Top
2021-09-23 $542.86 $558.71 $574.56
2021-09-24 $545.21 $561.06 $576.91
2021-09-27 $547.57 $563.42 $579.27
2021-09-28 $549.93 $565.78 $581.63
2021-09-29 $552.28 $568.13 $583.99
2021-09-30 $554.64 $570.49 $586.34
2021-10-01 $557.00 $572.85 $588.70
2021-10-04 $559.35 $575.20 $591.06
2021-10-05 $561.71 $577.56 $593.41
2021-10-06 $564.07 $579.92 $595.77
2021-10-07 $566.42 $582.28 $598.13
2021-10-08 $568.78 $584.63 $600.48
2021-10-11 $571.14 $586.99 $602.84
2021-10-12 $573.49 $589.35 $605.20
2021-10-13 $575.85 $591.70 $607.55
2021-10-14 $578.21 $594.06 $609.91
2021-10-15 $580.57 $596.42 $612.27
2021-10-18 $582.92 $598.77 $614.62
2021-10-19 $585.28 $601.13 $616.98
2021-10-20 $587.64 $603.49 $619.34
2021-10-21 $589.99 $605.84 $621.70
2021-10-22 $592.35 $608.20 $624.05
2021-10-25 $594.71 $610.56 $626.41
2021-10-26 $597.06 $612.91 $628.77
2021-10-27 $599.42 $615.27 $631.12
2021-10-28 $601.78 $617.63 $633.48
2021-10-29 $604.13 $619.99 $635.84
2021-11-01 $606.49 $622.34 $638.19
2021-11-02 $608.85 $624.70 $640.55
2021-11-03 $611.20 $627.06 $642.91

About DexCom

DexCom DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring systems in the United States and internationally. The company offers its systems for ambulatory use by people with diabetes; and for use by healthcare providers in the hospital for the treatment of patients with and without diabetes. Its ambulatory product line includes DexCom G4 PLATINUM system for continuous use by ... Read more

Golden Star Signal

This unique signal uses moving averages and adds special requirements that convert the very good Golden Cross into a Golden Star.

This signal is rare and, in most cases, gives substantial returns. From 10 000+ stocks usually only a few will trigger a Golden Star Signal per day!

Get access to Golden Star list now!

StockInvest.usJoin 95.000+ Happy Subscribers

Don't miss out on the runners!

Get The StockInvest.Us Newsletter

StockInvest.usStock Podcast

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT